Is Aspira Pathlab & Diagnostics Ltd (540788) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Aspira Pathlab & Diagnostics Ltd is a below average quality company .

Is Aspira Pathlab & Diagnostics Ltd (540788) undervalued or overvalued?

The key valuation ratios of Aspira Pathlab & Diagnostics Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Aspira Pathlab & Diagnostics Ltd (540788) share price return in the past 10 years?

Data is not available for this company

Is Aspira Pathlab & Diagnostics Ltd (540788) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aspira Pathlab & Diagnostics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Aspira Pathlab & Diagnostics Ltd (540788)?

Company share prices are keep on changing according to the market conditions. The current trading price of Aspira Pathlab & Diagnostics Ltd (540788) on 17-Apr-2026 16:59:59 at 16:59 is 59.35.

What is the P/E ratio of Aspira Pathlab & Diagnostics?

The latest standalone P/E ratio of Aspira Pathlab & Diagnostics as of 17-Apr-2026 is 41.67.

What is the P/B ratio of Aspira Pathlab & Diagnostics Ltd (540788)?

The latest standalone P/B ratio of Aspira Pathlab & Diagnostics Ltd (540788) as of 17-Apr-2026 is 4.75.

What is the 52-week high and low of Aspira Pathlab & Diagnostics Ltd (540788)?

The 52-week high of Aspira Pathlab & Diagnostics Ltd (540788) is Rs. 81.00 and the 52-week low is Rs. 49.00.

Aspira Pathlab & Diagnostics Ltd (540788) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Aspira Pathlab & Diagnostics Ltd (540788)
Brand: Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics Ltd (540788) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Aspira Pathlab & Diagnostics Ltd (540788)

BSE: 540788 NSE:

Key Metrics

Market Cap

₹61 Cr.

P/E Ratio

41.67

Price to Book (P/B)

4.75

Price to Sales (P/S)

2.52

EV/EBITDA

18.00

Return on Capital Employed (ROCE)

19.64%

Current Price

₹59.4

Return on Equity (ROE)

18.54%

Return on Assets (ROA)

12.86%

Operating Profit Margin

16.2%

Net Profit Margin

9.42%

Gross Profit Margin

16.2%

Book Value per Share

₹12.5

Sales Growth (YoY)

66.67%

Sales Growth (3 Years)

4.03%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

-17.72%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹49 / 81

Net Profit Growth (3 Years)

-22.54%

Dividend Yield

0.00%

Promoter Holding

18.39%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd revenue growth is 66.7% for FY-2025 , which is above its 5 year CAGR of 21.2% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Aspira Pathlab & Diagnostics Ltd?

Promoters hold 18.39% of the Aspira Pathlab & Diagnostics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Aspira Pathlab & Diagnostics Ltd vs industry peers?

Aspira Pathlab & Diagnostics Ltd revenue CAGR is 21.18% , compared to the industry median CAGR of 1.49% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Aspira Pathlab & Diagnostics Ltd belong to?

Aspira Pathlab & Diagnostics Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.

Q.1 Stock return of Aspira Pathlab & Diagnostics Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 15.8% based on the current price.

DeciZen - make an informed investing decision on Aspira Pathlab&Diagn

Based on:

Data

M-Cap below 100cr DeciZen not available

Aspira Pathlab & Diagnostics stock performance

Key Ratios

Is Aspira Pathlab & Diagnostics Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	1.8%	-25.4%	-38.4%	-34.5%	-26.3%	21.5%	41.6%	2.4%	-18.5%	19.6%	-
Value Creation Index ⓘ	-0.9	-2.8	-3.7	-3.5	-2.9	0.5	2.0	-0.8	-2.3	0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0.8	4.4	7.6	8.4	15.2	19.5	14.5	13.2	22	24
Sales YoY Gr.	-	NA	473.7%	75.2%	10.2%	80.6%	28.5%	-26%	-8.7%	66.7%	-
Adj EPS ⓘ	0.1	-5.3	-10.8	-6.3	-4.6	1.3	4.3	-0.1	-2.6	2	1.4
YoY Gr.	-	-4475%	NA	NA	NA	NA	223.1%	-102.1%	NA	NA	-
BVPS (₹) ⓘ	16.2	11.4	0.6	6.3	4.1	8.1	12.4	12.4	9.9	11.9	12.5
Adj Net Profit ⓘ	0	-2.7	-5.6	-5.2	-4.2	1.4	4.5	-0.1	-2.7	2.1	1
Cash Flow from Ops. ⓘ	-0.4	-1.3	-4.8	-3.4	-1.9	5.7	2	-0	1.1	1.9	-
Debt/CF from Ops. ⓘ	-7.2	-5.7	-2.4	-2.2	-4.2	0.2	0.4	-80.2	1	0.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	21.2%	4%	66.7%
Adj EPS ⓘ	37%	NA	-22.2%	NA
BVPSⓘ	-3.4%	23.8%	-1.5%	20.5%
Share Price	-	15.8%	22.9%	-9.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	0.8	-57	-178.6	-187.6	-94.3	22.8	42.3	-0.7	-23.3	18.7	11.7
Op. Profit Mgn % ⓘ	0	-339.5	-88.9	-42.5	-21.7	23.1	32.3	11	-9	16.2	11.8
Net Profit Mgn % ⓘ	0	-359.1	-128.1	-67.9	-50.4	9.1	22.8	-0.6	-20.2	9.5	6
Debt to Equity ⓘ	0.7	1.2	33.9	1.5	2	0.2	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	0	1,188	353	244	224	89	91	175	187	127	40
Cash Conv. Cycle ⓘ	0	40	25	32	29	17	45	80	59	29	23

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	1.4	2.3
TTM Sales (₹ Cr.)	24.2	22.6
BVPS (₹) ⓘ	12.5	12.3
Reserves (₹ Cr.) ⓘ	3	2
P/BV ⓘ	4.75	4.83
PE ⓘ	41.67	25.46

From the Market
52 Week Low / High (₹)	49.00 / 81.00
All Time Low / High (₹)	14.15 / 124.15
Market Cap (₹ Cr.)	61.1
Equity (₹ Cr.)	10.3
Face Value (₹)	10
Industry PE ⓘ	86.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Aspira Pathlab&Diagn - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	0	0.76	4.36	7.64	8.42	15.21	19.54	14.46	13.20	22
Operating Expenses ⓘ +	0.23	3.34	8.23	10.88	10.24	11.69	13.23	12.86	14.39	18.47
Manufacturing Costs	0.03	0.20	0.65	0.84	0.83	2.48	1.78	1.08	1.96	3.41
Material Costs	0	0.14	1.30	2.26	1.99	2.63	3.14	2.50	2.62	3.70
Employee Cost	0.08	1.61	3.42	4.47	4.95	4.03	5.02	5.59	6.20	7.33
Other Costs ⓘ	0.13	1.38	2.85	3.31	2.48	2.55	3.29	3.70	3.61	4.04
Operating Profit ⓘ	-0.23	-2.58	-3.87	-3.25	-1.83	3.51	6.32	1.59	-1.19	3.52
Operating Profit Margin (%)	-	-339.0%	-88.9%	-42.5%	-21.7%	23.1%	32.3%	11.0%	-9.0%	16.0%
Other Income ⓘ +	0.32	0.31	0.22	0.25	0.29	0.20	0.15	0.32	0.42	0.39
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.05	0.26	0.80	0.96	1.01	0.89	0.37	0.42	0.37	0.35
Depreciation ⓘ	0	0.20	1.12	1.23	1.66	1.44	1.64	1.59	1.54	1.49
Profit Before Tax ⓘ	0.04	-2.72	-5.58	-5.18	-4.21	1.38	4.46	-0.09	-2.67	2.07
Tax ⓘ	0.01	-0	0	0	0.03	0	0	0	0	0
Profit After Tax	0.03	-2.72	-5.58	-5.18	-4.24	1.38	4.46	-0.09	-2.67	2.07
PAT Margin (%)	-	-359.0%	-128.0%	-67.9%	-50.4%	9.1%	22.8%	-0.6%	-20.2%	9.4%
Adjusted EPS (₹)	0.1	-5.3	-10.8	-6.3	-4.6	1.3	4.3	-0.1	-2.6	2.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3.64	5.92	0.33	5.19	3.80	8.31	12.79	12.75	10.14	12.22
Share Capital ⓘ	2.25	5.19	5.19	8.19	9.29	10.29	10.29	10.29	10.29	10.29
Reserves ⓘ	1.39	0.72	-4.86	-3	-5.49	-1.98	2.50	2.46	-0.15	1.92
Debt +	2.62	6.79	10.59	6.75	6.87	0.77	0.86	0.96	1.08	1.21
Long Term Debt	0	3.17	10.50	4.78	4.55	0.77	0.86	0.96	1.08	1.21
Short Term Debt	2.62	3.61	0.09	1.96	2.32	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0	0.29	0.23	0.29	0.40	0.66	0.61	0.35	0.73	0.74
Others Liabilities ⓘ	0.03	1.87	1.38	2.57	3.26	2.03	3.88	3.28	2.76	3.35
Total Liabilities ⓘ	6.30	14.86	12.53	14.80	14.34	11.78	18.14	17.34	14.71	17.51
Fixed Assets
Net Fixed Assets ⓘ +	0.04	7.79	7.91	8.90	8.70	7.75	9.57	8.01	6.79	6.53
Gross Block	0.04	7.99	9.23	11.45	12.91	13.41	16.87	16.88	17.20	18.31
Accumulated Depreciation	0	0.20	1.33	2.55	4.21	5.66	7.29	8.88	10.41	11.78
CWIP ⓘ	0	0.25	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0.13
Inventories	0	0.12	0.37	0.28	0.28	0.37	0.40	0.40	0.45	0.51
Trade Receivables	0.06	0.09	0.35	0.80	0.60	1.70	4.49	2.34	2.24	2.35
Cash Equivalents	5.33	2.81	0.22	0.10	1.10	1.19	1.64	2.35	1.38	2.14
Others Assets ⓘ	0.87	3.81	3.68	4.73	3.66	0.77	2.02	4.25	3.85	5.85
Total Assets ⓘ	6.30	14.86	12.53	14.80	14.34	11.78	18.14	17.34	14.71	17.51

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.37	-1.29	-4.81	-3.39	-1.87	5.67	2.03	-0.01	1.05	1.88
PBT ⓘ	0.04	-2.72	-5.58	-5.18	-4.21	1.38	4.46	-0.09	-2.67	2.07
Adjustment ⓘ	-0.02	0.15	1.71	1.99	2.40	2.36	2.40	1.80	1.77	1.78
Changes in Working Capital ⓘ	-0.33	1.29	-0.94	-0.19	-0.03	1.93	-4.83	-1.73	1.96	-1.97
Tax Paid ⓘ	-0.05	0	0	-0	-0.03	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-0.02	-10.14	-0.77	-1.97	0.24	-0.09	-0.51	0.16	0.14	0.07
Capex	-0.04	-8.20	-1	-0.51	-0.05	-0.30	-0.61	-0.13	-0.26	-0.17
Net Investments	0	-2.25	0	-1.71	0	0	0	0	0	-0.13
Others ⓘ	0.02	0.31	0.22	0.25	0.29	0.20	0.09	0.29	0.40	0.37
Cash Flow From Financing Activity ⓘ +	2.64	8.91	6.52	3.35	1.27	-2.17	-1.35	-0.94	-0.95	-0.99
Net Proceeds from Shares ⓘ	0	5	0	5.10	2.86	3	0	0	0	0
Net Proceeds from Borrowing ⓘ	2.62	3.17	7.33	-6.29	-0.23	-3.78	0.09	0.10	0.12	0.13
Interest Paid ⓘ	0	-0.26	-0.80	-0.96	-1.01	-0.89	-0.37	-0.42	-0.37	-0.35
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.01	0.99	-0	5.50	-0.34	-0.50	-1.07	-0.62	-0.70	-0.78
Net Cash Flow ⓘ	2.25	-2.52	0.94	-2	-0.35	3.41	0.17	-0.79	0.24	0.95

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.76	-57.04	-178.61	-187.57	-94.32	22.8	42.26	-0.69	-23.34	18.54
ROCE (%)	1.78	-25.35	-38.38	-34.5	-26.3	21.52	41.63	2.4	-18.49	19.64
Asset Turnover Ratio	0	0.07	0.32	0.56	0.58	1.16	1.31	0.82	0.82	1.37
PAT to CFO Conversion(x)	-12.33	N/A	N/A	N/A	N/A	4.11	0.46	N/A	N/A	0.91
Working Capital Days
Receivable Days	0	35	19	28	30	28	58	86	63	38
Inventory Days	0	57	20	16	12	8	7	10	12	8
Payable Days	0	736	72	42	63	74	74	70	75	72

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aspira Pathlab & Diagnostics Ltd FAQs

The current trading price of Aspira Pathlab&Diagn on 17-Apr-2026 16:59 is ₹59.35.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Aspira Pathlab&Diagn stood at ₹61.09 Cr

The latest P/E ratio of Aspira Pathlab&Diagn as of 16-Apr-2026 is 41.67.

The latest P/B ratio of Aspira Pathlab&Diagn as of 16-Apr-2026 is 4.75.

The 52-week high of Aspira Pathlab&Diagn is ₹81.00 and the 52-week low is ₹49.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aspira Pathlab&Diagn is ₹24.24 ( Cr.) .

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited is a public limited company incorporated and domiciled in India. The company is engaged in the business of running, owning, managing and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.

It has its registered office at Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai, Maharashtra, India.

The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company’s performance, allocate resources based on the analysis of the various performance indicator of the Company as a single unit.

Business area of the company

The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Aspira Pathlab & Diagnostics Ltd (540788) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Aspira Pathlab&Diagn Share Price